2020 annual financial data
CRISPR Therapeutics 2020 Revenue growth
Direct answer
Revenue growth was -99.75%.
Operating income was -354,435,000 USD and net income was -348,865,000 USD.
Operating cash flow was -238,366,000 USD.
Get free CRISPR Therapeutics email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Revenue
- 719,000 USD
- Operating income
- -354,435,000 USD
- Net income
- -348,865,000 USD
- Operating cash flow
- -238,366,000 USD